Expert Opinion on Biological Therapy

Papers
(The TQCC of Expert Opinion on Biological Therapy is 9. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)
ArticleCitations
Platelet-rich plasma for the treatment of knee osteoarthritis: an expert opinion and proposal for a novel classification and coding system119
Adipose-derived stromal stem cells (ASCs) as a new regenerative immediate therapy combating coronavirus (COVID-19)-induced pneumonia65
Antibody-based immunotherapeutics and use of convalescent plasma to counter COVID-19: advances and prospects61
Addressing high dose AAV toxicity – ‘one and done’ or ‘slower and lower’?61
Mesothelin-targeted CAR-T cell therapy for solid tumors58
Development of SARS-CoV-2 vaccines: should we focus on mucosal immunity?57
Recent developments of RNA-based vaccines in cancer immunotherapy56
Status update in the use of cell-penetrating peptides for the delivery of macromolecular therapeutics55
Sacituzumab govitecan, a novel, third-generation, antibody-drug conjugate (ADC) for cancer therapy54
Antibody-drug conjugates (ADCs) delivering pyrrolobenzodiazepine (PBD) dimers for cancer therapy50
Core decompression isolated or combined with bone marrow-derived cell therapies for femoral head osteonecrosis46
Will plant-made biopharmaceuticals play a role in the fight against COVID-19?43
Brexucabtagene autoleucel for the treatment of relapsed/refractory mantle cell lymphoma41
An overview of process development for antibody-drug conjugates produced by chemical conjugation technology40
One-year effectiveness, retention rate, and safety of secukinumab in ankylosing spondylitis and psoriatic arthritis: a real-life multicenter study40
Therapeutic monoclonal antibodies for COVID-19 management: an update39
New frontiers in personalized medicine in psoriasis37
Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 Pandemic: Risk analysis from the PSO-BIO-COVID observational study36
A review of antibody-based therapeutics targeting G protein-coupled receptors: an update34
A tool with many applications: vesicular stomatitis virus in research and medicine34
Targeting the complement system in neuromyelitis optica spectrum disorder33
Immunotherapy for SARS-CoV-2: potential opportunities31
Nivolumab for the treatment of hepatocellular carcinoma30
Treating psoriasis in the elderly: biologics and small molecules30
Progress with stem cell therapies for tendon tissue regeneration30
A comprehensive review on sarilumab in COVID-1930
A randomized blinded retrospective study: the combined use of micro-needling technique, low-level laser therapy and autologous non-activated platelet-rich plasma improves hair re-growth in patients wi29
Antibody-drug conjugates in metastatic triple negative breast cancer: a spotlight on sacituzumab govitecan, ladiratuzumab vedotin, and trastuzumab deruxtecan27
The potential role of tumor-derived exosomes in diagnosis, prognosis, and response to therapy in cancer27
Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in breast cancer therapeutics26
Itolizumab, an anti-CD6 monoclonal antibody, as a potential treatment for COVID-19 complications26
Enzyme therapy: a forerunner in catalyzing a healthy society?24
A health economic guide to market access of biosimilars24
Anti-CD20 treatment for B-cell malignancies: current status and future directions23
Anticalin® proteins: from bench to bedside23
Immune checkpoint inhibition in COVID-19: risks and benefits23
Biologic therapy for advanced breast cancer: recent advances and future directions23
Tafasitamab for the treatment of relapsed or refractory diffuse large B-cell lymphoma23
Tumor-infiltrating lymphocytes for adoptive cell therapy: recent advances, challenges, and future directions22
Lymphodepletion strategies to potentiate adoptive T-cell immunotherapy – what are we doing; where are we going?22
What makes a good antibody–drug conjugate?22
Isatuximab for the treatment of relapsed/refractory multiple myeloma21
Regenerative medicine for spinal cord injury: focus on stem cells and biomaterials21
Regenerative application of stromal vascular fraction cells enhanced fat graft maintenance: clinical assessment in face rejuvenation21
Hemophilia A gene therapy: current and next-generation approaches21
Abicipar pegol for neovascular age-related macular degeneration21
HLA-Cw6 and other HLA-C alleles, as well as MICB-DT, DDX58, and TYK2 genetic variants associate with optimal response to anti-IL-17A treatment in patients with psoriasis21
Margetuximab for the treatment of HER2-positive metastatic breast cancer21
AIRMESS – Academy of International Regenerative Medicine & Surgery Societies: recommendations in the use of platelet-rich plasma (PRP), autologous stem cell-based therapy (ASC-BT) in androgenetic 20
The effect of platelet-rich plasma-fibrin glue dressing in combination with oral vitamin E and C for treatment of non-healing diabetic foot ulcers: a randomized, double-blind, parallel-group, clinical20
A two-arm, randomized, controlled, multi-centric, open-label phase-2 study to evaluate the efficacy and safety of Itolizumab in moderate to severe ARDS patients due to COVID-1920
One-year effectiveness and safety of ustekinumab in ulcerative colitis: a multicenter real-world study from Italy20
Small extracellular vesicles (sEVs): discovery, functions, applications, detection methods and various engineered forms20
Atezolizumab in the treatment of metastatic triple-negative breast cancer20
Targeting Toll-like receptor 3 in dendritic cells for cancer immunotherapy19
Developments in reading frame restoring therapy approaches for Duchenne muscular dystrophy19
Circumventing the packaging limit of AAV-mediated gene replacement therapy for neurological disorders18
Use of brodalumab for the treatment of chronic plaque psoriasis: a one-year real-life study in the Lazio region, Italy18
Therapeutic potential of biologics in prurigo nodularis18
COVID-19 pneumonia and immune-related pneumonitis: critical issues on differential diagnosis, potential interactions, and management18
Rotavirus vaccines: progress and new developments18
Enfortumab vedotin – next game-changer in urothelial cancer17
Cell therapy for type 1 diabetes17
Efficacy and safety of intravitreal anti-VEGF therapy in diabetic retinopathy: what we have learned and what should we learn further?17
Progress in the use of plasma rich in growth factors in ophthalmology: from ocular surface to ocular fundus17
PanErbB-targeted CAR T-cell immunotherapy of head and neck cancer17
Dupilumab for the treatment of chronic rhinosinusitis with nasal polyposis17
B7-H3 targeted antibody-based immunotherapy of malignant diseases17
Biologics in severe asthma: the overlap endotype - opportunities and challenges16
HIV-1 cure strategies: why CRISPR?16
Tocilizumab: from the rheumatology practice to the fight against COVID-19, a virus infection with multiple faces16
Trastuzumab deruxtecan in HER2-positive metastatic breast cancer and beyond16
Prostate cancer immunotherapy16
The evolution of bispecific antibodies15
Status of a real-life cohort of patients with moderate-to-severe plaque psoriasis treated with secukinumab and considerations on the use of biological agents in the Covid-19 era15
Rationale and clinical development of CD40 agonistic antibodies for cancer immunotherapy15
Antibody-drug conjugates for multiple myeloma15
Ranibizumab for the treatment of diabetic retinopathy15
Targeting nectin-4 by antibody-drug conjugates for the treatment of urothelial carcinoma14
Targeting MSS colorectal cancer with immunotherapy: are we turning the corner?14
Engineering vaccinia virus as an immunotherapeutic battleship to overcome tumor heterogeneity14
RNA therapeutics for retinal diseases14
Current and emerging biologics for the treatment of neuromyelitis optica spectrum disorders14
Rituximab treatment of ANCA-associated vasculitis13
Gemtuzumab ozogamicin for the treatment of acute myeloid leukemia in adults13
An inflammatory triangle in Sarcoidosis: PPAR-γ, immune microenvironment, and inflammation13
Anti-IL-5 monoclonal antibodies for the treatment of asthma: an update13
Injectable and adhesive hydrogels for dealing with wounds13
The impact of anti-TNFα agents on weight-related changes: new insights from a real-world pharmacovigilance study using the FDA adverse event reporting system (FAERS) database13
Brolucizumab: a novel anti-VEGF humanized single-chain antibody fragment for treating w-AMD13
Survivin as a biological biomarker for diagnosis and therapy13
Onasemnogene abeparvovec for the treatment of spinal muscular atrophy13
CGRP pathway monoclonal antibodies for cluster headache13
Toripalimab for the treatment of melanoma13
Treatment of cerebral adrenoleukodystrophy: allogeneic transplantation and lentiviral gene therapy12
Pembrolizumab for the treatment of esophageal cancer12
Emerging vistas in CAR T-cell therapy: challenges and opportunities in solid tumors12
A Randomized Controlled Ixekizumab Vs Secukinumab Trial to Study the Impact on Sexual Activity in Adult Patients with Genital Psoriasis12
Clinical development of retroviral replicating vector Toca 511 for gene therapy of cancer12
Conventional type 1 dendritic cells (cDC1) as cancer therapeutics: challenges and opportunities12
Ranibizumab for myopic choroidal neovascularization12
Nocebo effect and biosimilars in inflammatory bowel diseases: what’s new and what’s next?12
Targeting glyco-immune checkpoints for cancer therapy12
Adeno-associated virus (AAV) capsid engineering in liver-directed gene therapy12
Luspatercept for β-thalassemia: beyond red blood cell transfusions12
Self-administration of omalizumab: why not? A literature review and expert opinion12
Comparison of short- and long-term effectiveness of ixekizumab and secukinumab in real-world practice12
Denosumab for cancer-related bone loss12
Liver-directed gene-based therapies for inborn errors of metabolism11
Pembrolizumab for the treatment of Hodgkin Lymphoma11
The use of anti-TNF-alpha therapies for patients with systemic lupus erythematosus. Where are we now?11
Combination of immune checkpoint inhibitors and tyrosine kinase inhibitors for the treatment of renal cell carcinoma11
Similar efficacy, safety, and immunogenicity of the biosimilar BI 695501 and adalimumab reference product in patients with moderate-to-severe chronic plaque psoriasis: results from the randomized Phas11
A review of imlifidase in solid organ transplantation11
Ustekinumab for treating ulcerative colitis: an expert opinion11
Eculizumab for the treatment of myasthenia gravis11
Biologics in food allergy: up-to-date11
Combining anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) and -programmed cell death protein 1 (PD-1) agents for cancer immunotherapy10
Antibody–drug conjugates to treat gastric cancer10
IL-23 inhibition for the treatment of psoriatic arthritis10
Ligelizumab for the treatment of chronic spontaneous urticaria10
Arming cytotoxic lymphocytes for cancer immunotherapy by means of the NKG2D/NKG2D-ligand system10
Guselkumab for the treatment of psoriasis: a 60-week real-life multicenter retrospective experience10
Current and emerging biologic therapies for triple negative breast cancer10
Anthrax prevention through vaccine and post-exposure therapy10
Antibody-drug conjugates for the treatment of ovarian cancer10
Immune checkpoint inhibitors for the treatment of melanoma10
Guselkumab for the treatment of palmoplantar pustulosis10
Bispecific antibodies for the treatment of breast cancer10
Up-to-date role of biologics in the management of respiratory syncytial virus10
Cord blood transplantation for acute leukemia10
Oncolytic virus therapy for malignant gliomas: entering the new era9
Avelumab: search for combinations of immune checkpoint inhibition with chemotherapy9
Harmonizing PD-L1 testing in metastatic triple negative breast cancer9
Evaluation of canine bone marrow-derived mesenchymal stem cells for experimental full-thickness cutaneous wounds in a diabetic rat model9
Anti-programmed cell death-1 and anti-programmed cell death ligand-1 immune-related liver diseases: from clinical pivotal studies to real-life experience9
Anti-tumor necrosis factor agents in psoriasis: addressing key challenges using biosimilars9
Anti-IFNαR Mabs for the treatment of systemic lupus erythematosus9
Place in therapy of anti-IL-17 and 23 in psoriasis according to the severity of comorbidities: a focus on cardiovascular disease and metabolic syndrome9
Gene Therapy for High Grade Glioma: The Clinical Experience9
Will the US$5 million onasemnogene abeparvosec treatment for spinal muscular atrophy represent ‘value for money’ for the NHS? A rapid inquiry into suggestions that it may be cost-effective9
CRISPR/Cas9 gene editing therapies for cystic fibrosis9
Alternative therapeutic strategy for existing aortic aneurysms using mesenchymal stem cell–derived exosomes9
Brolucizumab ─ termination of 4 weekly trials ─ rebalancing the immunogenicity risk9
Immunotherapy-chemotherapy combinations for non-small cell lung cancer: current trends and future perspectives9
Tildrakizumab for treatment of moderate to severe psoriasis: an expert opinion of efficacy, safety, and use in special populations9
AAV5-miHTT gene therapy for Huntington disease: lowering both huntingtins9
Evolution of infliximab biosimilar in inflammatory bowel disease: from intravenous to subcutaneous CT-P139
Belimumab: a step forward in the treatment of systemic lupus erythematosus9
Real-world observational study of biosimilars in inflammatory arthritis treatment: a systematic literature review9
0.056997776031494